Wuhan Hongren Biopharmaceutical Inc. – FDA Inspection, Sep 4, 2024

Record Details

This FDA Inspection record concerns Wuhan Hongren Biopharmaceutical Inc., with an inspection on September 4, 2024, issued by the Office of Inspections and Investigations, covering human drugs.

Company: Wuhan Hongren Biopharmaceutical Inc.
Inspection Date: September 4, 2024
Product Type: Human Drugs
Office: Office of Inspections and Investigations
Person: Rafeeq A. Habeeb (FDA Associated Person)

View Company Profile

ID · 3d97762a-976d-4d9b-a61b-19099401db0d

Inspection Facts

Inspection number: 1251337
FDA center: Human Drugs
Outcome: Form 483 issued, view the record

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Wuhan Hongren Biopharmaceutical Inc.

FDA Inspection

Wuhan Hongren Biopharmaceutical Inc.September 4, 2024

Wuhan Hongren Biopharmaceutical Inc. – FDA Inspection, Sep 4, 2024

Record Details

This FDA Inspection record concerns Wuhan Hongren Biopharmaceutical Inc., with an inspection on September 4, 2024, issued by the Office of Inspections and Investigations, covering human drugs.